Previous meta-analysis in non-transplant CKD patients have shown promising results for SGLT-2 inhibitors in reducing composite CV death or hospitalization for heart failure, with a remarkable 23% decrease compared to placebo. The gene discussed is SLC5A2; the disease is heart failure.